Research
Hormonal
Historical obesity pharmacotherapies utilizing thyroid hormones, sympathomimetics, and serotonergic agents were withdrawn due to severe cardiovascular, psychiatric, or oncological toxicity, despite demonstrating weight loss efficacy.
Do not use historical weight loss drugs like thyroid hormones, amphetamines, or fenfluramine. They are dangerous and have been withdrawn from the market due to severe side effects like heart damage and death. Modern treatments focus on safer mechanisms like GLP-1 agonists.
StrongRefutesHIGH confidence
Many drugs that were investigated and used for weight loss were subsequently withdrawn from the market due to safety issues. ... Until recently, long-term effective and safe pharmacotherapy of obesity remained an insurmountable challenge.
Why this rating
Based on a comprehensive review of clinical trials and regulatory withdrawals.
Source
The history of the pharmacotherapy of obesity
M A Berkovskaya et al. · Problems of Endocrinology · 2025
DOI 10.14341/probl13469
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →